Clinical Trial Update: Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel after cisplatin-based chemotherapy and surgery for high-risk bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN